Tirzepatide vs Semaglutide: Head to Head Comparison

Both drugs evolved from the discovery of GLP-1, a gut hormone that controls appetite and blood sugar. The first GLP-1 agonist, exenatide, was approved for diabetes in 2005. It worked, but required twice-daily injections and produced modest weight loss. Semaglutide was developed by Novo Nordisk as a once-weekly GLP-1 agonist with improved potency and a longer half-life than previous GLP-1 drugs. It was approved for diabetes as Ozempic in 2017 and for obesity as Wegovy in 2021. The STEP trial program showed 15 to 17 percent body weight loss, which was a massive jump from the 8 percent seen with liraglutide. Tirzepatide was developed by Eli Lilly as the first dual GIP/GLP-1 receptor agonist. It was approved for diabetes as Mounjaro in 2022 and for obesity as Zepbound in 2023. The SURMOUNT trials showed 20 to 25 percent body weight loss, surpassing semaglutide by a meaningful margin. The race between these two drugs has defined modern obesity treatment. Novo Nordisk responded by developing higher-dose semaglutide formulations and oral versions. Eli Lilly is pushing further with triple agonists and next-generation compounds. For now, tirzepatide and semaglutide are the head to head matchup everyone is watching.

Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone, binding to GLP-1 receptors in the brain, pancreas, and gut. In the brain, it reduces appetite and food cravings. In the pancreas, it improves insulin secretion. In the gut, it slows gastric emptying so you feel full longer after eating. Tirzepatide is a dual GIP/GLP-1 receptor agonist. It does everything semaglutide does, plus it activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are found in the brain, pancreas, fat tissue, and bone. The GIP component appears to enhance the weight loss effect beyond what GLP-1 alone achieves. Why does GIP matter? The full answer is still being studied. GIP receptors in fat tissue may improve fat metabolism. GIP receptors in the brain may complement the appetite-suppressing effects of GLP-1. Some researchers think GIP activation reduces the nausea side effect commonly seen with pure GLP-1 agonists, though this is debated. Both drugs are injected subcutaneously once weekly. Semaglutide is titrated up from 0.25mg to a maintenance dose of 1mg, 1.7mg, or 2.4mg (Wegovy goes to 2.4mg). Tirzepatide is titrated from 2.5mg to a maintenance dose of 5mg, 7.5mg, 10mg, 12.5mg, or 15mg.

The numbers from clinical trials are clear. Semaglutide (Wegovy, 2.4mg):

• Average weight loss: 15.8 percent over 68 weeks (STEP 1 trial)
• 83 percent of participants lost at least 5 percent of body weight
• 66 percent lost at least 10 percent
• 48 percent lost at least 15 percent

Tirzepatide (Zepbound, 15mg):

• Average weight loss: 22.5 percent over 72 weeks (SURMOUNT-1 trial)
• 96 percent of participants lost at least 5 percent of body weight
• 91 percent lost at least 10 percent
• 84 percent lost at least 15 percent
• 57 percent lost at least 20 percent

In a head to head trial (SURMOUNT-5), tirzepatide produced 20.2 percent weight loss versus 13.7 percent for semaglutide over 72 weeks. That is a 6.5 percentage point advantage, which is clinically meaningful. Blood sugar control: Both drugs lower HbA1c significantly. Tirzepatide tends to produce slightly better glucose control in diabetes trials, likely due to the GIP component. Cardiovascular outcomes: Semaglutide has published cardiovascular outcomes data showing reduced heart attack and stroke risk in people with obesity and cardiovascular disease. Tirzepatide cardiovascular outcomes data is still being collected but is expected to show similar benefits.

The appetite suppression effect is similar for both drugs. The main difference users report is side effect intensity. A user on r/Mounjaro shared: “Switched from 1mg Ozempic to 7.5mg Mounjaro. The appetite suppression was similar, maybe slightly stronger on Mounjaro. But the nausea was way less. On Ozempic I was dealing with nausea 2 to 3 days after each shot. On Mounjaro it is maybe the first day, mild, and then gone.“ A user on r/Ozempic wrote: “I have been on semaglutide for 8 months. Down 52 pounds. I considered switching to tirzepatide but my insurance only covers Ozempic. Honestly the results have been great. I might have lost more on tirzepatide, but 52 pounds is life-changing. Not sure I need to optimize further.“ The practical difference in daily experience is subtle. Both drugs suppress appetite, reduce food noise, and slow digestion. Tirzepatide may produce slightly less nausea, possibly because the GIP component has a protective effect on the gut. But individual variation is large.

With semaglutide:

• Strong appetite suppression within the first week
• Reduced cravings for sugar and processed food
• Feeling full after smaller portions
• Steady weight loss of 1 to 2 pounds per week
• Improved blood sugar control
• Potential cardiovascular benefits

With tirzepatide:

• All of the above, plus potentially greater weight loss
• Possibly less nausea than semaglutide at equivalent doses
• Better blood sugar control in head to head diabetes trials
• Higher percentage of people reaching 15 to 20 percent weight loss

Without insurance, both drugs are expensive. Semaglutide (Wegovy): approximately $1,350 per month at full retail price. Tirzepatide (Zepbound): approximately $1,060 per month at full retail price. Compounding pharmacy versions are much cheaper: Compounded semaglutide: $150 to $400 per month depending on dose and pharmacy. Compounded tirzepatide: $200 to $500 per month. Insurance coverage is variable. Most insurers cover GLP-1 drugs for diabetes (Ozempic, Mounjaro) more readily than for obesity (Wegovy, Zepbound). Coverage for obesity indication is expanding but still inconsistent. Some plans require prior authorization, step therapy, or BMI documentation.

Choose semaglutide if:

• You have cardiovascular risk factors (semaglutide has published CV outcomes data)
• Your insurance covers Ozempic or Wegovy
• You want the longest track record (approved since 2017)
• You are comfortable with 15 percent weight loss as a target

Choose tirzepatide if:

• You want maximum weight loss potential (20 to 25 percent)
• You experienced significant nausea on semaglutide
• You have type 2 diabetes and need superior glucose control
• Cost is a factor (Zepbound is slightly cheaper at retail than Wegovy)

Both are good drugs. The “best“ one depends on your goals, your body's response, insurance coverage, and tolerance for side effects.